Clinical Utility of Caduet in Achieving Blood Pressure and Lipid Endpoints in a Specific Patient Population
CAPABLE
Clinical Utility Of Caduet In Simultaneously Achieving Blood Pressure And Lipid Endpoints In A Specific Patient Population (CAPABLE)
1 other identifier
interventional
500
1 country
106
Brief Summary
The purpose is to demonstrate the utility of Caduet (amlodipine/atorvastatin) in the African American population
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_4 hypertension
Started Jul 2004
Shorter than P25 for phase_4 hypertension
106 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2004
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2005
CompletedFirst Submitted
Initial submission to the registry
September 6, 2005
CompletedFirst Posted
Study publicly available on registry
September 8, 2005
CompletedJanuary 27, 2021
January 1, 2021
September 6, 2005
January 26, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
To evaluate the efficacy of Caduet therapy by assessing the percentage of intent-to-treat subjects achieving both BP and lipid treatment goals (JNC VII and NCEP ATP III)
Secondary Outcomes (1)
To assess the percentage of subjects achieving treatment goals(JNC VII and NCEP) stratified by the final BP and lipid therapy doses, respectively, the change from baseline in lipid profile, SBP and DBP
Interventions
Eligibility Criteria
You may qualify if:
- African American men and women with concurrent hypertension and dyslipidemia that is either treated or untreated
You may not qualify if:
- Subjects currently being treated with concomitant amlodipine and atorvastatin therapy, including Caduet
- Subjects with blood pressure at goal
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (106)
Pfizer Investigational Site
Birmingham, Alabama, 35209, United States
Pfizer Investigational Site
Birmingham, Alabama, 35211, United States
Pfizer Investigational Site
Huntsville, Alabama, 35801, United States
Pfizer Investigational Site
Little Rock, Arkansas, 72204, United States
Pfizer Investigational Site
Los Angeles, California, 90024, United States
Pfizer Investigational Site
Oakland, California, 94609-3425, United States
Pfizer Investigational Site
Pico Rivera, California, 90660, United States
Pfizer Investigational Site
Bridgeport, Connecticut, 6610, United States
Pfizer Investigational Site
Washington D.C., District of Columbia, 20010, United States
Pfizer Investigational Site
Washington D.C., District of Columbia, 20037, United States
Pfizer Investigational Site
Aventura, Florida, 33180, United States
Pfizer Investigational Site
Gainesville, Florida, 32601, United States
Pfizer Investigational Site
Jacksonville, Florida, 32204, United States
Pfizer Investigational Site
Orlando, Florida, 32806, United States
Pfizer Investigational Site
Pensacola, Florida, 32503, United States
Pfizer Investigational Site
Vero Beach, Florida, 32960, United States
Pfizer Investigational Site
Athens, Georgia, 30606, United States
Pfizer Investigational Site
Atlanta, Georgia, 30303, United States
Pfizer Investigational Site
Atlanta, Georgia, 30309, United States
Pfizer Investigational Site
Atlanta, Georgia, 30310, United States
Pfizer Investigational Site
Atlanta, Georgia, 30342, United States
Pfizer Investigational Site
Augusta, Georgia, 30904, United States
Pfizer Investigational Site
Columbus, Georgia, 31901, United States
Pfizer Investigational Site
Columbus, Georgia, 31904, United States
Pfizer Investigational Site
Decatur, Georgia, 30033, United States
Pfizer Investigational Site
Lincolnton, Georgia, 30817, United States
Pfizer Investigational Site
Savannah, Georgia, 31406, United States
Pfizer Investigational Site
Chicago, Illinois, 60616, United States
Pfizer Investigational Site
Chicago, Illinois, 60637-1470, United States
Pfizer Investigational Site
Maywood, Illinois, 60153, United States
Pfizer Investigational Site
Merrillville, Indiana, 46410, United States
Pfizer Investigational Site
Overland Park, Kansas, 66211, United States
Pfizer Investigational Site
Bossier City, Louisiana, 71111, United States
Pfizer Investigational Site
New Orleans, Louisiana, 70117-4817, United States
Pfizer Investigational Site
New Orleans, Louisiana, 70125, United States
Pfizer Investigational Site
Shreveport, Louisiana, 71101, United States
Pfizer Investigational Site
Shreveport, Louisiana, 71130, United States
Pfizer Investigational Site
Baltimore, Maryland, 21201, United States
Pfizer Investigational Site
Baltimore, Maryland, 21215, United States
Pfizer Investigational Site
Columbia, Maryland, 21045, United States
Pfizer Investigational Site
Randallstown, Maryland, 21133, United States
Pfizer Investigational Site
Rockville, Maryland, 20850, United States
Pfizer Investigational Site
Westminster, Maryland, 21157, United States
Pfizer Investigational Site
Brockton, Massachusetts, 02301, United States
Pfizer Investigational Site
Wellesley Hills, Massachusetts, 02481-2106, United States
Pfizer Investigational Site
Detroit, Michigan, 48201, United States
Pfizer Investigational Site
Detroit, Michigan, 48235, United States
Pfizer Investigational Site
Lansing, Michigan, 48917, United States
Pfizer Investigational Site
Livonia, Michigan, 48152, United States
Pfizer Investigational Site
Jackson, Mississippi, 39202, United States
Pfizer Investigational Site
Jackson, Mississippi, 39216, United States
Pfizer Investigational Site
Kansas City, Missouri, 64112, United States
Pfizer Investigational Site
Kansas City, Missouri, 64131, United States
Pfizer Investigational Site
St Louis, Missouri, 63104, United States
Pfizer Investigational Site
St Louis, Missouri, 63110, United States
Pfizer Investigational Site
St Louis, Missouri, 63141, United States
Pfizer Investigational Site
Cherry Hill, New Jersey, 08034, United States
Pfizer Investigational Site
East Orange, New Jersey, 07018, United States
Pfizer Investigational Site
Elizabeth, New Jersey, 07202, United States
Pfizer Investigational Site
Hammonton, New Jersey, 08037, United States
Pfizer Investigational Site
South Bound Brook, New Jersey, 08880, United States
Pfizer Investigational Site
Voorhees Township, New Jersey, 08043, United States
Pfizer Investigational Site
Woodbury, New Jersey, 08096, United States
Pfizer Investigational Site
Brooklyn, New York, 11203, United States
Pfizer Investigational Site
Brooklyn, New York, United States
Pfizer Investigational Site
Buffalo, New York, 14215, United States
Pfizer Investigational Site
Mineola, New York, 11501, United States
Pfizer Investigational Site
Charlotte, North Carolina, 28209, United States
Pfizer Investigational Site
Greenville, North Carolina, 27834, United States
Pfizer Investigational Site
Monroe, North Carolina, 28112, United States
Pfizer Investigational Site
Monroe, North Carolina, United States
Pfizer Investigational Site
Winston-Salem, North Carolina, 27103-3315, United States
Pfizer Investigational Site
Winston-Salem, North Carolina, 27103, United States
Pfizer Investigational Site
Cincinnati, Ohio, 45219, United States
Pfizer Investigational Site
Cincinnati, Ohio, 45229, United States
Pfizer Investigational Site
Cincinnati, Ohio, 45236, United States
Pfizer Investigational Site
Cincinnati, Ohio, 45246, United States
Pfizer Investigational Site
Dayton, Ohio, 45402, United States
Pfizer Investigational Site
Dayton, Ohio, 45406, United States
Pfizer Investigational Site
Maumee, Ohio, 43537, United States
Pfizer Investigational Site
Perrysburg, Ohio, 43551, United States
Pfizer Investigational Site
Bensalem, Pennsylvania, 19020, United States
Pfizer Investigational Site
Philadelphia, Pennsylvania, 19141, United States
Pfizer Investigational Site
Philadelphia, Pennsylvania, 19146, United States
Pfizer Investigational Site
Philadelphia, Pennsylvania, 19148, United States
Pfizer Investigational Site
Bamberg, South Carolina, 29003, United States
Pfizer Investigational Site
Charleston, South Carolina, 29425, United States
Pfizer Investigational Site
Clinton, South Carolina, 29325, United States
Pfizer Investigational Site
Mt. Pleasant, South Carolina, 29464, United States
Pfizer Investigational Site
Simpsonville, South Carolina, 29681, United States
Pfizer Investigational Site
Bartlett, Tennessee, 38134, United States
Pfizer Investigational Site
Jackson, Tennessee, 38305, United States
Pfizer Investigational Site
Beaumont, Texas, 77702, United States
Pfizer Investigational Site
Dallas, Texas, 75235, United States
Pfizer Investigational Site
Dallas, Texas, 75254, United States
Pfizer Investigational Site
Houston, Texas, 77024, United States
Pfizer Investigational Site
Houston, Texas, 77030, United States
Pfizer Investigational Site
Houston, Texas, 77054, United States
Pfizer Investigational Site
Emporia, Virginia, 23847, United States
Pfizer Investigational Site
Norfolk, Virginia, 23502, United States
Pfizer Investigational Site
Norfolk, Virginia, 23510, United States
Pfizer Investigational Site
Richmond, Virginia, 23249, United States
Pfizer Investigational Site
Richmond, Virginia, 23294, United States
Pfizer Investigational Site
Virginia Beach, Virginia, 23454, United States
Pfizer Investigational Site
Virginia Beach, Virginia, 23455, United States
Pfizer Investigational Site
Milwaukee, Wisconsin, 53209, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Pfizer CT.gov Call Center
Pfizer
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 6, 2005
First Posted
September 8, 2005
Study Start
July 1, 2004
Study Completion
August 1, 2005
Last Updated
January 27, 2021
Record last verified: 2021-01